edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Cantargia
Edison Investment Research has terminated coverage on Cantargia (CANTA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing antibodies against target IL1RAP to treat cancer and autoimmune diseases. Lead antibody CAN04 is currently being studied in a Phase I/II study in solid tumours focusing on NSCLC and pancreatic cancer. In this video, the company’s chief executive officer Göran Forsberg introduces the company and its lead asset, and provides an overview of R&D progress and expected newsflow.
Get access to the very latest content matched to your personal investment style.